following an abbreviated submission:
ublituximab (Briumvi®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
SMC restriction: treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Ublituximab offers an additional treatment choice in the therapeutic class of anti-CD20 monoclonal antibodies.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice278KB (PDF)
Medicine details
- Medicine name:
- ublituximab (Briumvi)
- SMC ID:
- SMC2731
- Indication:
For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
- Pharmaceutical company
- Neuraxpharm UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 13 January 2025